Chronic liver injury in rats and humans upregulates the novel enzyme angiotensin converting enzyme 2.
BACKGROUND
Angiotensin converting enzyme (ACE) 2 is a recently identified homologue of ACE that may counterregulate the actions of angiotensin (Ang) II by facilitating its breakdown to Ang 1-7. The renin-angiotensin system (RAS) has been implicated in the pathogenesis of cirrhosis but the role of ACE2 in liver disease is not known.


OBJECTIVE
This study examined the effects of liver injury on ACE2 expression and activity in experimental hepatic fibrosis and human cirrhosis, and the effects of Ang 1-7 on vascular tone in cirrhotic rat aorta.


METHODS
In sham operated and bile duct ligated (BDL) rats, quantitative reverse transcriptase-polymerase chain reaction was used to assess hepatic ACE2 mRNA, and western blotting and immunohistochemistry to quantify and localise ACE2 protein. ACE2 activity was quantified by quenched fluorescent substrate assay. Similar studies were performed in normal human liver and in hepatitis C cirrhosis.


RESULTS
ACE2 mRNA was detectable at low levels in rat liver and increased following BDL (363-fold; p < 0.01). ACE2 protein increased after BDL (23.5-fold; p < 0.05) as did ACE2 activity (fourfold; p < 0.05). In human cirrhotic liver, gene (>30-fold), protein expression (97-fold), and activity of ACE2 (2.4 fold) were increased compared with controls (all p < 0.01). In healthy livers, ACE2 was confined to endothelial cells, occasional bile ducts, and perivenular hepatocytes but in both BDL and human cirrhosis there was widespread parenchymal expression of ACE2 protein. Exposure of cultured human hepatocytes to hypoxia led to increased ACE2 expression. In preconstricted rat aorta, Ang 1-7 alone did not affect vascular tone but it significantly enhanced acetylcholine mediated vasodilatation in cirrhotic vessels.


CONCLUSIONS
ACE2 expression is significantly increased in liver injury in both humans and rat, possibly in response to increasing hepatocellular hypoxia, and may modulate RAS activity in cirrhosis.
Paizis
G
G
University of Melbourne, Department of Medicine, Austin Health, Heidelberg, Victoria, Australia.
Tikellis
C
C
Cooper
M E
ME
Schembri
J M
JM
Lew
R A
RA
Smith
A I
AI
Shaw
T
T
Warner
F J
FJ
Zuilli
A
A
Burrell
L M
LM
Angus
P W
PW
D000803:Angiotensin I / Q000494:pharmacology; D000085962:Angiotensin-Converting Enzyme 2; D000818:Animals; D001013:Aorta, Thoracic / Q000187:drug effects / Q000502:physiology; D002268:Carboxypeptidases / Q000378:metabolism*; D015687:Cell Hypoxia; D002478:Cells, Cultured; D002908:Chronic Disease; D004195:Disease Models, Animal; D005260:Female; D019698:Hepatitis C, Chronic / Q000150:complications / Q000201:enzymology; D022781:Hepatocytes / Q000201:enzymology; D006801:Humans; D007124:Immunoenzyme Techniques; D008099:Liver / Q000201:enzymology; D008103:Liver Cirrhosis / Q000201:enzymology* / Q000821:virology; D008297:Male; D009593:Nitroimidazoles / Q000378:metabolism; D010446:Peptide Fragments / Q000494:pharmacology; D007703:Peptidyl-Dipeptidase A; D051381:Rats; D017207:Rats, Sprague-Dawley; D020133:Reverse Transcriptase Polymerase Chain Reaction / Q000379:methods; D015854:Up-Regulation; D014664:Vasodilation / Q000187:drug effects
D009593:Nitroimidazoles; D010446:Peptide Fragments; C033815:pimonidazole; D000803:Angiotensin I; D002268:Carboxypeptidases; D007703:Peptidyl-Dipeptidase A; C000705307:ACE2 protein, human; C000705329:Ace2 protein, rat; D000085962:Angiotensin-Converting Enzyme 2; C118790:angiotensin I (1-7)